SCHEMBL5572610

SCHEMBL5572610

O=C(C=CC=Cc1ccc(C(F)(F)F)cc1)N1CCN(CCCN2CCN(C(=O)C=CC=Cc3ccc(C(F)(F)F)cc3)CC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 8/20 0.52
CYP1A2 P05177 1/20 0.48
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
DRD2 P14416 1/20 0.44
DRD3 P35462 1/20 0.44
KCNH2 Q12809 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
MAOB P27338 2/20 0.43
ALOX5 P09917 1/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
TP53 P04637 2/20 0.43
HPGD P15428 1/20 0.43
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5572606 1.00 GPR183 (0.52) GPR183CYP1A2KEAP1NFE2L2DRD2
Hydrochloric Acid SCHEMBL5573117 0.99 GPR183 (0.51) GPR183CYP1A2KEAP1NFE2L2DRD2
Hydrochloric Acid SCHEMBL5573111 0.99 GPR183 (0.51) GPR183CYP1A2KEAP1NFE2L2DRD2
SCHEMBL6787409 0.86 ALDH1A1 (0.57) GPR183CYP1A2MAOBALOX5ALDH1A1
SCHEMBL5569629 0.84 GPR183 (0.56) GPR183CYP1A2DRD2DRD3MAOB
SCHEMBL5570675 0.84 GPR183 (0.56) GPR183CYP1A2DRD2DRD3MAOB
Hydrochloric Acid SCHEMBL5570669 0.83 GPR183 (0.55) GPR183CYP1A2DRD2DRD3MAOB
Hydrochloric Acid SCHEMBL5570664 0.83 GPR183 (0.55) GPR183CYP1A2DRD2DRD3MAOB
SCHEMBL19385657 0.75 GPR183 (0.67) GPR183CYP1A2KCNH2HRH3ALDH1A1
SCHEMBL19385656 0.75 GPR183 (0.67) GPR183CYP1A2KCNH2HRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1057815-B1 CYCLIC AMIDE COMPOUNDS KOWA CO (JP) 2007-09-05 EP disclosed
US-6645957-B2 Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis KOWA CO., LTD. (JP) 2003-11-11 US disclosed
US-20030096828-A1 Cyclic amide compound KOWA CO., LTD. (JP) 2003-05-22 US disclosed
US-6448242-B1 COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS KOWA CO., LTD. (JP) 2002-09-10 US disclosed
EP-1057815-A1 CYCLIC AMIDE COMPOUNDS Kowa Co., Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096828-A1 Cyclic amide compound CMA1, HRH2, HRH4 GPR183 1967/4885CYP1A2 516/4885KEAP1 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.